130 related articles for article (PubMed ID: 17296644)
1. Safety of sputum induction during exacerbations of COPD.
Bathoorn E; Liesker J; Postma D; Koëter G; van Oosterhout AJ; Kerstjens HA
Chest; 2007 Feb; 131(2):432-8. PubMed ID: 17296644
[TBL] [Abstract][Full Text] [Related]
2. The safety of sputum induction in adults with acute exacerbation of COPD.
Gao P; Gibson PG; Zhang J; He X; Hao Y; Li P; Liu H
Clin Respir J; 2013 Jan; 7(1):101-9. PubMed ID: 22452898
[TBL] [Abstract][Full Text] [Related]
3. The success and safety profile of sputum induction in patients with chronic obstructive pulmonary disease: An Indian experience.
Fernandes L; Mesquita AM
Indian J Tuberc; 2017 Jul; 64(3):201-205. PubMed ID: 28709489
[TBL] [Abstract][Full Text] [Related]
4. Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation.
Tufvesson E; Bjermer L; Ekberg M
Int J Chron Obstruct Pulmon Dis; 2015; 10():881-9. PubMed ID: 26005341
[TBL] [Abstract][Full Text] [Related]
5. Dyspnea assessment and adverse events during sputum induction in COPD.
Makris D; Tzanakis N; Moschandreas J; Siafakas NM
BMC Pulm Med; 2006 Jun; 6():17. PubMed ID: 16808839
[TBL] [Abstract][Full Text] [Related]
6. [Metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in induced sputum in patients with asthma and chronic obstructive pulmonary disease and their relationship to airway inflammation and airflow limitation].
Xin XF; Zhao M; Li ZL; Song Y; Shi Y
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Mar; 30(3):192-6. PubMed ID: 17572998
[TBL] [Abstract][Full Text] [Related]
7. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease.
Taube C; Holz O; Mücke M; Jörres RA; Magnussen H
Am J Respir Crit Care Med; 2001 Nov; 164(10 Pt 1):1810-5. PubMed ID: 11734428
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
9. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.
Seemungal TA; Donaldson GC; Bhowmik A; Jeffries DJ; Wedzicha JA
Am J Respir Crit Care Med; 2000 May; 161(5):1608-13. PubMed ID: 10806163
[TBL] [Abstract][Full Text] [Related]
10. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and airway inflammation profile of COPD persistent sputum producers.
Khurana S; Ravi A; Sutula J; Milone R; Williamson R; Plumb J; Vestbo J; Singh D
Respir Med; 2014 Dec; 108(12):1761-70. PubMed ID: 25459449
[TBL] [Abstract][Full Text] [Related]
12. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.
Patel IS; Seemungal TA; Wilks M; Lloyd-Owen SJ; Donaldson GC; Wedzicha JA
Thorax; 2002 Sep; 57(9):759-64. PubMed ID: 12200518
[TBL] [Abstract][Full Text] [Related]
13. Changes in sputum composition during 15 min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease.
Toungoussova O; Migliori GB; Foschino Barbaro MP; Esposito LM; Dragonieri S; Carpagnano GE; Salerno FG; Neri M; Spanevello A
Respir Med; 2007 Jul; 101(7):1543-8. PubMed ID: 17258444
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of sputum induction in lung transplant recipients.
van den Berg JW; Slebos DJ; Postma DS; Dijkhuizen B; Koëter GH; Timens W; der van Bij W; Kauffman HF
Clin Transplant; 2004 Oct; 18(5):605-12. PubMed ID: 15344968
[TBL] [Abstract][Full Text] [Related]
15. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability.
Brightling CE; Monterio W; Green RH; Parker D; Morgan MD; Wardlaw AJ; Pavord D
Respir Med; 2001 Dec; 95(12):999-1002. PubMed ID: 11778799
[TBL] [Abstract][Full Text] [Related]
16. Impaired perception of dyspnea in patients with severe asthma. Relation to sputum eosinophils.
Veen JC; Smits HH; Ravensberg AJ; Hiemstra PS; Sterk PJ; Bel EH
Am J Respir Crit Care Med; 1998 Oct; 158(4):1134-41. PubMed ID: 9769272
[TBL] [Abstract][Full Text] [Related]
17. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease.
Hacievliyagil SS; Gunen H; Mutlu LC; Karabulut AB; Temel I
Respir Med; 2006 May; 100(5):846-54. PubMed ID: 16214322
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease.
Wilkinson TM; Donaldson GC; Johnston SL; Openshaw PJ; Wedzicha JA
Am J Respir Crit Care Med; 2006 Apr; 173(8):871-6. PubMed ID: 16456141
[TBL] [Abstract][Full Text] [Related]
19. [Safety of sputum induction in interstitial lung disease].
Sobiecka M; Kuś J
Pneumonol Alergol Pol; 2008; 76(1):11-8. PubMed ID: 18283650
[TBL] [Abstract][Full Text] [Related]
20. Exhaled Hydrogen Sulfide Predicts Airway Inflammation Phenotype in COPD.
Zhang J; Wang X; Chen Y; Yao W
Respir Care; 2015 Feb; 60(2):251-8. PubMed ID: 25336529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
